Ten Takeover Targets
Last month, I published a list of ten takeover targets in the biopharmaceutical sector. I have noted that all ten stocks have risen, with a few over 20%. Importantly, there was an acquisition announcement of one of the stocks this morning, as Lilly intends to buy Verve Therapeutics for $10.50 per share, which represents a 67% premium.
The bigger picture…
Keep reading with a 7-day free trial
Subscribe to Len Yaffe to keep reading this post and get 7 days of free access to the full post archives.